Pulmonary Disease, Chronic ObstructiveNCT01779960
Summer-Winter Variability in the Level of Physical Activity in Daily Life in Brazilian and Belgian Patients With COPD
An observational study of Pulmonary Disease, Chronic Obstructive, run by Universidade Estadual de Londrina at 2 sites in 2 countries.
Trial summary
Up to this moment, the majority of studies assessing the level of physical activity in daily life in patients with COPD are limited to a cross-sectional design, which does not take into account natural variation of physical activity in daily life due to differences in climatic conditions faced throughout the year. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Pulmonary Disease, Chronic Obstructive
- What is being tested?
- Londrina and Leuven
- How many people
- 40 participants
- Where
- 2 sitesin 2 countries
- Study dates
- Jan 2013to Nov 2015
- How long will I take part?
- 6 Months
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: The sample will be composed by at least 35 patients with moderate-severe COPD from each institution involved (Catholic University of Leuven, Belgium and State University of Londrina, Brazil), adding up to 70 patients. However, the sample size could be increased if necessary to achieve intermediate calculation of the sample power performed during the study. Both groups should be similar concerning anthropometric characteristics, gender distribution and severity feature of the disease (especially FEV1). Therefore, an eventual increase in the final number of patients may also be necessary in case this similarity is not achieved in the final data collection of the planned sample.
Who may be able to join
- Diagnosis of COPD based on internationally accepted criteria
- Clinical stability (absence of exacerbations) for at least 3 months before inclusion in the study
- Absence of orthopedic comorbidities which could interfere on the performance of the proposed assessments
Who cannot join
- Patients will be excluded of the study if they do not demonstrate physical or cognitive conditions to complete the proposed assessments,
- If they suffer from a moderate or severe acute exacerbation in the period between the two assessment points
- If they decide to leave the study for any reason
Trial locations and contacts
2 sites in 2 countries.
2 sites in 2 countries
Belgium1 site, 1 recruiting
- Recruiting
University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Belgium
Leuven
Thierry Troosters, PhD, Thierry.Troosters@med.kuleuven.be
Carlos A. Camillo, MSc, carlosaugustocamillo@yahoo.com.br
Brazil1 site, 1 recruiting
- Recruiting
University Hospital Londrina , Universidade Estadual de Londrina, Brasil
Londrina, Paraná
Fabio Pitta, PhD, +55 43 33712477, fabiopitta@uol.com.br
Karina Furlanetto, PT, +55 43 33712477, ka_furlanetto@hotmail.com
About this study
Official title: Understanding in Depth the Physical Inactivity of Patients With COPD: Comparison of the Summer-Winter Variability in the Level of Physical Activity in Daily Life in Brazilian and Belgian Patients
Up to this moment, the majority of studies assessing the level of physical activity in daily life in patients with COPD are limited to a cross-sectional design, which does not take into account natural variation of physical activity in daily life due to differences in climatic conditions faced throughout the year. Preliminary evidences suggest that patients with COPD have different physical activity levels according to the seasons of the year. However, the limited current evidences do not allow us to know the magnitude of differences in the level of daily physical activity in patients with COPD when taking into account climatic changes resulting from different seasons of the year in cities and countries with contrasting climatic conditions. This gap observed in the literature does not allow us at this moment to know whether we should or not consider the season of the year as one of the main causes of variability while assessing physical activity in daily life in patients with COPD.
The present project proposes to investigate the hypothesis that patients with COPD who live in a place with less marked decrease in temperature between summer and winter (Londrina, Brazil) have less variability in the level of physical activity in daily life through the year in comparison to patients who live in a place with more marked climatic variability during these seasons (Leuven, Belgium).
Read the detailed description
The sample will be composed by at least 20 patients with moderate-severe COPD from each institution involved (Catholic University of Leuven, Belgium and State University of Londrina, Brazil), adding up to 40 patients (see sample size calculation below). However, the sample size could be increased if necessary to achieve intermediate calculation of the sample power performed during the study. Both groups should be similar concerning anthropometric characteristics, gender distribution and severity feature of the disease (especially FEV1). Therefore, an eventual increase in the final number of patients may also be necessary in case this similarity is not achieved in the final data collection of the planned sample.
Data collection will be performed in the Laboratory of Research in Respiratory Physiotherapy from the State University of Londrina (Londrina, Brazil) and in the University Hospital Gasthuisberg from the Catholic University of Leuven (Leuven, Belgium).
The study has a longitudinal design. Two groups of patients, one group in Londrina and another group in Leuven, will be simultaneously and objectively evaluated concerning their physical activity in daily life during one week in two different moments: in January 2013 (winter in Leuven and summer in Londrina), and then the same two groups of patients will be once again simultaneously re-evaluated during another week in July 2013 (summer in Leuven and winter in Londrina). Changes in the level of physical activity in daily life between summer and winter in the two groups will then be compared. Monitoring of physical activity in daily life: two activity monitors (the SenseWear armband and the Fitbit) will be simultaneously worn during 7 consecutive days. The SenseWear armband (BodyMedia, Pittsburg, PA, USA) is a multisensor composed by a biaxial accelerometer and physiologic sensors. It is a small (8.8 x 5.6 x 2 cm) and lightweight (82g) monitor that is worn at the upper right arm and was already validated for energy expenditure estimation in patients with COPD [12,13]. The Fitbit (Fitbit, Inc., San Francisco, CA, USA) is a recently released triaxial accelerometer that is smaller (3.6 x 2.9 x 1 cm) and more lightweight (8g) than the SenseWear. According to the manufacturer, the Fitbit can be used in different positions, including at the waist. This device provides the number of steps, the distance walked and the energy expenditure in calories, among other variables. In the 7 days of assessment, the patient will remain with the device during 24 hours/day. The patients will be strictly instructed to avoid changing their daily physical activity habits during the monitoring period.
To characterize the sample, all patients will be submitted to spirometry, 6 minute walking test (6MWT) and quality of life assessment (Chronic Respiratory Disease Questionnaire - CRQ), also described in detail in the subsection "Methods".
For each patient, further information will be also registered: types of drugs used by the patient, their dosage and how often these drugs are used in the last month before inclusion in the study; characterization of the history of acute exacerbations occurred in the last year (if it is the case); presence of respiratory insufficiency on admission or during the study period (PaO2 < 60 mmHg and/or SpO2 < 90% with or without PaCo2 > 50 mmHg, breathing on room air); need for long-term oxygen supplementation previously or during the study period; practice or not of regular physical activity in the last year.
LOGISTICS INVOLVED IN DATA COLECTION IN BOTH CENTERS
In the first period of data collection (January 2013), the Brazilian coordinator of the project (Prof. Fabio Pitta) will travel to Leuven to participate in data collection and organization on site. The Brazilian project coordinator will arrive in Leuven two weeks before the data collection, and in conjunction with the Belgian coordinator of the project (Prof. Thierry Troosters) and the European researchers will prepare all necessary logistic actions to ensure the adequate performance of the study. After the preparation period, data collection itself will be performed in three weeks, with 15 patients being assessed in the first week and 14 in the third week. Spirometry, 6MWT and CRQ will be performed on Friday, and data collection of physical activity will be performed from Saturday to next week's Saturday. The 1-week interval between the first and second weeks of assessment will be used to download the data and discuss eventual issues raised in the first week of assessment, and thus this justifies the need of 15 activity monitor devices (SenseWear and Fitbit) in each center adding up to 60 necessary devices (as data collection will simultaneously occur in both centers).
Previously, the Brazilian team involved in the project will be prepared by the Brazilian coordinator with the same instruction, since the first period of data collection in Londrina will occur simultaneously with Leuven. Therefore, the first period of data collection in Londrina will be performed by the Brazilian researchers involved in the study, coordinated from Leuven by Prof. Fabio Pitta. The research team will make sure that the Brazilian researchers are prepared and trained to perform all assessments, including the objective quantification of physical activity in daily life, as well as the identical application of the 6MWT and CRQ in both centers.
In the second phase of data collection (July 2013), the European and the Brazilian researchers will be responsible for the assessments with the same protocol trained and performed in the first phase of data collection. Therefore, Prof. Fabio Pitta will coordinate the data collection in Londrina while Prof. Thierry Troosters will coordinate the data collection in Leuven to ensure the reproducibility of all the methods in the second data collection moment..
After the second phase of data collection, further project activities will have the coordination centralized in Londrina, with the Brazilian coordinator of the project.
STATISTICAL ANALYSIS AND SAMPLE SIZE CALCULATION
Statistical analysis will be performed using the SPSS v. 17 Statistical Package (SPSS, Inc., Chicago IL, EUA) and the GraphPad Prism 5.0 (GraphPad Software Inc., San Diego, CA, EUA). The Shapiro-Wilk test will be initially used to analyze the normality in data distribution. In case of variables normally distributed, data will be described as mean ± standard deviation, and those variables with non-normal distribution will be described as median [25%-75% interquartile range]. Summer-winter changes in the same group of patients will be analyzed by the paired t test (parametric analysis) or the Wilcoxon test (non-parametric analysis). Summer-winter differences between the two groups of patients (Londrina and Leuven) will be analyzed by the unpaired t test (parametric analysis) or by the Mann-Whitney (non-parametric analysis). Variables of spirometry, 6MWT and CRQ of both groups will be analyzed by the unpaired t test in the two assessment moments. Correlations will be analyzed by the Pearson or Spearman coefficient, depending on the normality on data distribution. For all analysis, statistical significance will be set at p less than 0.05.
The sample size of the study was calculated according to the assumption of a mean (and standard deviation) difference of counts/day between two groups of patients with COPD, being one in Europe and one in Brazil. The first group was assessed in the summer and winter, as found in the study by Sewell et al. performed in England [10]. This study presented a mean difference of 5656 counts (8857 in summer and 3201 in winter), with a standard deviation of 7497 and 2629 counts, respectively. The second group was based on our hypothesis that there will be no (or little) change in physical activity in daily life due to seasonal variation in Londrina (Brasil) based on the study by Probst et al. (Respiratory Care 2011; 56[11]: 1799-87), taking into account a similar standard deviation of 5063 counts/day. With a power of 90%, alfa coefficient of 0.05, at least 12 patients in each group will be necessary to detect significant difference in the level of physical activity in daily life between summer and winter within the groups. Taking into account an eventual difficult setting with drop-out rate of 40% due to difficulties in the data collection protocol involving the motion sensors, a minimum of 20 patients will be included to compose either group (Londrina and Leuven), adding up to 40 patients in total.
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Being tested
- Londrina, Leuven
- Keywords
- Pulmonary Disease, Chronic Obstructive, Motor activity, Climatologic station
- Medical subject headings
- Pulmonary Disease, Chronic Obstructive, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
LondrinaOther
Also called Climatologic Station
Two groups of patients, one group in Londrina and another group in Leuven, will be simultaneously and objectively evaluated concerning their physical activity in daily life during one week in two different moments: in January 2013 (winter in Leuven and summer in Londrina), and then the same two groups of patients will be once again simultaneously re-evaluated during another week in July 2013 (summer in Leuven and winter in Londrina).
LeuvenOther
Also called Climatologic Station
Two groups of patients, one group in Londrina and another group in Leuven, will be simultaneously and objectively evaluated concerning their physical activity in daily life during one week in two different moments: in January 2013 (winter in Leuven and summer in Londrina), and then the same two groups of patients will be once again simultaneously re-evaluated during another week in July 2013 (summer in Leuven and winter in Londrina).
| Study group | Role | What they receive |
|---|---|---|
| Londrina | 20 patients with moderate-severe COPD from State University of Londrina, Brazi Receives: Other: Londrina | |
| Leuven | 20 patients with moderate-severe COPD from Catholic University of Leuven, Belgium Receives: Other: Leuven |
What is being measured
The primary outcome is the main question the study is designed to answer.
Physical activity in daily life
Two activity monitors (the SenseWear armband and the Fitbit) will be simultaneously worn during 7 consecutive days. The SenseWear armband (BodyMedia, Pittsburg, PA, USA) is a multisensor composed by a biaxial accelerometer and physiologic sensors. It is a small (8.8 x 5.6 x 2 cm) and lightweight (82g) monitor that was already validated for energy expenditure estimation in patients with COPD. The Fitbit (Fitbit, Inc., San Francisco, CA, USA) is a recently released triaxial accelerometer that is smaller (3.6 x 2.9 x 1 cm) and more lightweight (8g) than the SenseWear. This device provides the number of steps, the distance walked and the energy expenditure in calories, among other variables. In the 7 days of assessment, the patient will remain with the device during 24 hours/day. The patients will be strictly instructed to avoid changing their daily physical activity habits during the monitoring period.
Measured: January 2013 and July 2013. Participants will be followed for the duration of 6 months.
Secondary outcomes (3)
Six minute walking test
Two tests will be performed with 30 minutes of interval, according to international standards. Subjects will be encouraged to walk during 6 minutes as fast as possible in a straight leveled 30-meter corridor. Reference values will be those by Troosters et al.
Measured: January 2013 and July 2013. Participants will be followed for the duration of 6 months.
Spirometry
Pulmonary function test (post-bronchodilator spirometry) measuring slow vital capacity (SVC), forced expiratory volume in the first second (FEV1), forced vital capacity (FVC), and FEV1/FVC ratio will be performed by the use of a hand-held spirometer (Spiropalm, Cosmed, Italy), following the American Thoracic Society - European Respiratory Society (ATS-ERS) standardized protocol [14] and based on the reference values by Pereira et al. for Brazilian patients and Knudson et al. for European patients.
Measured: January 2013 and July 2013. Participants will be followed for the duration of 6 months.
Chronic Respiratory Disease Questionnaire (CRQ)
The CRQ contains 20 questions divided in 4 domains: dyspnea (5 questions), fatigue (4 questions), emotional function (7 questions) and self control (4 questions). The dyspnea domain is individualized, which means that each patient selects from a list the activities which induce dyspnea in the last two weeks, and they can report other activities that are not on the list. Subsequently, among the reported and selected activities, the patient chooses 5 activities considered the most important ones and by the use of a scale of 7 points the patient grades how much dyspnea interferes on these activities. In this scale the score ranges from 1 (maximum impairment) to 7 (no impairment at all). Concerning the other domains (fatigue, emotional function and self control), the questions are standardized and the patient answers each question using the scale of 7 points. The results are presented on average score of each domain, and the higher the score, the better the subject quality of life.
Measured: January 2013 and July 2013. Participants will be followed for the duration of 6 months.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Jan 2013 (estimated)
- Study startJan 2013
- Primary completionAug 2015 (estimated)
- Study completionNov 2015 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pulmonary Disease, Chronic ObstructiveStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Time perspective
- Prospective
- Enrolment
- 40 participants (estimated)
- Target duration
- 6 Months
Sponsor and investigators
- Lead sponsor
- Universidade Estadual de Londrina
- Sponsor type
- University, hospital or other
- Collaborators
- KU Leuven
- Responsible party
- Principal investigator, Fabio Pitta, PhD, Universidade Estadual de Londrina
- Investigators
- Fabio Pitta, PhD, Study chair, Laboratory of Research in Respiratory Physiotherapy, State University of Londrina, BrazilKarina C. Furlanetto, PT, Study director, Laboratory of Research in Respiratory Physiotherapy, State University of Londrina, BrazilNidia A. Hernandes, PhD, Principal investigator, Laboratory of Research in Respiratory Physiotherapy, State University of Londrina, BrazilThais Sant'Anna, MSc, Principal investigator, Laboratory of Research in Respiratory Physiotherapy, State University of Londrina, BrazilVanessa S. Probst, PhD, Principal investigator, Laboratory of Research in Respiratory Physiotherapy, State University of Londrina, BrazilThierry Troosters, PhD, Study chair, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, BelgiumHeleen Demeyer, PT, Study director, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, BelgiumCarlos A. Camillo, MSc, Principal investigator, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Belgium
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01779960
- Sponsor's protocol ID
- LFIP-001-KCF-1
- Other IDs
- 483107/2011-5
- Status last verified
- Jun 2015
- First submitted
- 28 Jan 2013
- Last updated
- 11 Jun 2015
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Jun 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Understanding in Depth the Physical Inactivity of Patients With COPD: Comparison of the Summer-Winter Variability in the Level of Physical Activity in Daily Life in Brazilian and Belgian Patients
- ClinicalTrials.gov ID
- NCT01779960
- Acronym / sponsor ID
- LFIP-001-KCF-1
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Keywords
- Pulmonary Disease, Chronic Obstructive, Motor activity, Climatologic station
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Universidade Estadual de LondrinaUniversity, hospital or other
- Collaborators
- KU Leuven
- Study start
- Jan 2013
- Primary completion
- Aug 2015 (estimated)
- Study completion
- Nov 2015 (estimated)
- First posted
- 30 Jan 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Up to this moment, the majority of studies assessing the level of physical activity in daily life in patients with COPD are limited to a cross-sectional design, which does not take into account natural variation of physical activity in daily life due to differences in climatic conditions faced throughout the year. Preliminary evidences suggest that patients with COPD have different physical activity levels according to the seasons of the year. However, the limited current evidences do not allow us to know the magnitude of differences in the level of daily physical activity in patients with COPD when taking into account climatic changes resulting from different seasons of the year in cities and countries with contrasting climatic conditions. This gap observed in the literature does not allow us at this moment to know whether we should or not consider the season of the year as one of the main causes of variability while assessing physical activity in daily life in patients with COPD.
The present project proposes to investigate the hypothesis that patients with COPD who live in a place with less marked decrease in temperature between summer and winter (Londrina, Brazil) have less variability in the level of physical activity in daily life through the year in comparison to patients who live in a place with more marked climatic variability during these seasons (Leuven, Belgium).
Detailed description
The sample will be composed by at least 20 patients with moderate-severe COPD from each institution involved (Catholic University of Leuven, Belgium and State University of Londrina, Brazil), adding up to 40 patients (see sample size calculation below). However, the sample size could be increased if necessary to achieve intermediate calculation of the sample power performed during the study. Both groups should be similar concerning anthropometric characteristics, gender distribution and severity feature of the disease (especially FEV1). Therefore, an eventual increase in the final number of patients may also be necessary in case this similarity is not achieved in the final data collection of the planned sample.
Data collection will be performed in the Laboratory of Research in Respiratory Physiotherapy from the State University of Londrina (Londrina, Brazil) and in the University Hospital Gasthuisberg from the Catholic University of Leuven (Leuven, Belgium).
The study has a longitudinal design. Two groups of patients, one group in Londrina and another group in Leuven, will be simultaneously and objectively evaluated concerning their physical activity in daily life during one week in two different moments: in January 2013 (winter in Leuven and summer in Londrina), and then the same two groups of patients will be once again simultaneously re-evaluated during another week in July 2013 (summer in Leuven and winter in Londrina). Changes in the level of physical activity in daily life between summer and winter in the two groups will then be compared. Monitoring of physical activity in daily life: two activity monitors (the SenseWear armband and the Fitbit) will be simultaneously worn during 7 consecutive days. The SenseWear armband (BodyMedia, Pittsburg, PA, USA) is a multisensor composed by a biaxial accelerometer and physiologic sensors. It is a small (8.8 x 5.6 x 2 cm) and lightweight (82g) monitor that is worn at the upper right arm and was already validated for energy expenditure estimation in patients with COPD [12,13]. The Fitbit (Fitbit, Inc., San Francisco, CA, USA) is a recently released triaxial accelerometer that is smaller (3.6 x 2.9 x 1 cm) and more lightweight (8g) than the SenseWear. According to the manufacturer, the Fitbit can be used in different positions, including at the waist. This device provides the number of steps, the distance walked and the energy expenditure in calories, among other variables. In the 7 days of assessment, the patient will remain with the device during 24 hours/day. The patients will be strictly instructed to avoid changing their daily physical activity habits during the monitoring period.
To characterize the sample, all patients will be submitted to spirometry, 6 minute walking test (6MWT) and quality of life assessment (Chronic Respiratory Disease Questionnaire - CRQ), also described in detail in the subsection "Methods".
For each patient, further information will be also registered: types of drugs used by the patient, their dosage and how often these drugs are used in the last month before inclusion in the study; characterization of the history of acute exacerbations occurred in the last year (if it is the case); presence of respiratory insufficiency on admission or during the study period (PaO2 < 60 mmHg and/or SpO2 < 90% with or without PaCo2 > 50 mmHg, breathing on room air); need for long-term oxygen supplementation previously or during the study period; practice or not of regular physical activity in the last year.
LOGISTICS INVOLVED IN DATA COLECTION IN BOTH CENTERS
In the first period of data collection (January 2013), the Brazilian coordinator of the project (Prof. Fabio Pitta) will travel to Leuven to participate in data collection and organization on site. The Brazilian project coordinator will arrive in Leuven two weeks before the data collection, and in conjunction with the Belgian coordinator of the project (Prof. Thierry Troosters) and the European researchers will prepare all necessary logistic actions to ensure the adequate performance of the study. After the preparation period, data collection itself will be performed in three weeks, with 15 patients being assessed in the first week and 14 in the third week. Spirometry, 6MWT and CRQ will be performed on Friday, and data collection of physical activity will be performed from Saturday to next week's Saturday. The 1-week interval between the first and second weeks of assessment will be used to download the data and discuss eventual issues raised in the first week of assessment, and thus this justifies the need of 15 activity monitor devices (SenseWear and Fitbit) in each center adding up to 60 necessary devices (as data collection will simultaneously occur in both centers).
Previously, the Brazilian team involved in the project will be prepared by the Brazilian coordinator with the same instruction, since the first period of data collection in Londrina will occur simultaneously with Leuven. Therefore, the first period of data collection in Londrina will be performed by the Brazilian researchers involved in the study, coordinated from Leuven by Prof. Fabio Pitta. The research team will make sure that the Brazilian researchers are prepared and trained to perform all assessments, including the objective quantification of physical activity in daily life, as well as the identical application of the 6MWT and CRQ in both centers.
In the second phase of data collection (July 2013), the European and the Brazilian researchers will be responsible for the assessments with the same protocol trained and performed in the first phase of data collection. Therefore, Prof. Fabio Pitta will coordinate the data collection in Londrina while Prof. Thierry Troosters will coordinate the data collection in Leuven to ensure the reproducibility of all the methods in the second data collection moment..
After the second phase of data collection, further project activities will have the coordination centralized in Londrina, with the Brazilian coordinator of the project.
STATISTICAL ANALYSIS AND SAMPLE SIZE CALCULATION
Statistical analysis will be performed using the SPSS v. 17 Statistical Package (SPSS, Inc., Chicago IL, EUA) and the GraphPad Prism 5.0 (GraphPad Software Inc., San Diego, CA, EUA). The Shapiro-Wilk test will be initially used to analyze the normality in data distribution. In case of variables normally distributed, data will be described as mean ± standard deviation, and those variables with non-normal distribution will be described as median [25%-75% interquartile range]. Summer-winter changes in the same group of patients will be analyzed by the paired t test (parametric analysis) or the Wilcoxon test (non-parametric analysis). Summer-winter differences between the two groups of patients (Londrina and Leuven) will be analyzed by the unpaired t test (parametric analysis) or by the Mann-Whitney (non-parametric analysis). Variables of spirometry, 6MWT and CRQ of both groups will be analyzed by the unpaired t test in the two assessment moments. Correlations will be analyzed by the Pearson or Spearman coefficient, depending on the normality on data distribution. For all analysis, statistical significance will be set at p less than 0.05.
The sample size of the study was calculated according to the assumption of a mean (and standard deviation) difference of counts/day between two groups of patients with COPD, being one in Europe and one in Brazil. The first group was assessed in the summer and winter, as found in the study by Sewell et al. performed in England [10]. This study presented a mean difference of 5656 counts (8857 in summer and 3201 in winter), with a standard deviation of 7497 and 2629 counts, respectively. The second group was based on our hypothesis that there will be no (or little) change in physical activity in daily life due to seasonal variation in Londrina (Brasil) based on the study by Probst et al. (Respiratory Care 2011; 56[11]: 1799-87), taking into account a similar standard deviation of 5063 counts/day. With a power of 90%, alfa coefficient of 0.05, at least 12 patients in each group will be necessary to detect significant difference in the level of physical activity in daily life between summer and winter within the groups. Taking into account an eventual difficult setting with drop-out rate of 40% due to difficulties in the data collection protocol involving the motion sensors, a minimum of 20 patients will be included to compose either group (Londrina and Leuven), adding up to 40 patients in total.
Study design
- Time perspective
- Prospective
- Target follow-up
- 6 Months
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Londrina | – | Other: Londrina20 patients with moderate-severe COPD from State University of Londrina, Brazi |
| Leuven | – | Other: Leuven20 patients with moderate-severe COPD from Catholic University of Leuven, Belgium |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- The sample will be composed by at least 35 patients with moderate-severe COPD from each institution involved (Catholic University of Leuven, Belgium and State University of Londrina, Brazil), adding up to 70 patients. However, the sample size could be increased if necessary to achieve intermediate calculation of the sample power performed during the study. Both groups should be similar concerning anthropometric characteristics, gender distribution and severity feature of the disease (especially FEV1). Therefore, an eventual increase in the final number of patients may also be necessary in case this similarity is not achieved in the final data collection of the planned sample.
Key inclusion criteria (3 listed)
- Diagnosis of COPD based on internationally accepted criteria
- Clinical stability (absence of exacerbations) for at least 3 months before inclusion in the study
- Absence of orthopedic comorbidities which could interfere on the performance of the proposed assessments
Key exclusion criteria (3 listed)
- Patients will be excluded of the study if they do not demonstrate physical or cognitive conditions to complete the proposed assessments,
- If they suffer from a moderate or severe acute exacerbation in the period between the two assessment points
- If they decide to leave the study for any reason
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| LondrinaAlso: Climatologic StationTwo groups of patients, one group in Londrina and another group in Leuven, will be simultaneously and objectively evaluated concerning their physical activity in daily life during one week in two different moments: in January 2013 (winter in Leuven and summer in Londrina), and then the same two groups of patients will be once again simultaneously re-evaluated during another week in July 2013 (summer in Leuven and winter in Londrina). | Other | Londrina |
| LeuvenAlso: Climatologic StationTwo groups of patients, one group in Londrina and another group in Leuven, will be simultaneously and objectively evaluated concerning their physical activity in daily life during one week in two different moments: in January 2013 (winter in Leuven and summer in Londrina), and then the same two groups of patients will be once again simultaneously re-evaluated during another week in July 2013 (summer in Leuven and winter in Londrina). | Other | Leuven |
Primary outcome
Physical activity in daily life
Time frame: January 2013 and July 2013. Participants will be followed for the duration of 6 months.
Two activity monitors (the SenseWear armband and the Fitbit) will be simultaneously worn during 7 consecutive days. The SenseWear armband (BodyMedia, Pittsburg, PA, USA) is a multisensor composed by a biaxial accelerometer and physiologic sensors. It is a small (8.8 x 5.6 x 2 cm) and lightweight (82g) monitor that was already validated for energy expenditure estimation in patients with COPD. The Fitbit (Fitbit, Inc., San Francisco, CA, USA) is a recently released triaxial accelerometer that is smaller (3.6 x 2.9 x 1 cm) and more lightweight (8g) than the SenseWear. This device provides the number of steps, the distance walked and the energy expenditure in calories, among other variables. In the 7 days of assessment, the patient will remain with the device during 24 hours/day. The patients will be strictly instructed to avoid changing their daily physical activity habits during the monitoring period.
3 secondary outcomes
Six minute walking test
Time frame: January 2013 and July 2013. Participants will be followed for the duration of 6 months.
Spirometry
Time frame: January 2013 and July 2013. Participants will be followed for the duration of 6 months.
Chronic Respiratory Disease Questionnaire (CRQ)
Time frame: January 2013 and July 2013. Participants will be followed for the duration of 6 months.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Jun 2015.
Related trials for Pulmonary Disease, Chronic Obstructive
Active, not recruiting
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
COPD, Smoking
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Not yet recruiting
The Aim of the Study is to Decipher the Alterations in Signalling Pathways of Skeletal Muscle Stem Cells (Satellite Cells (SCs)) in Individuals With COPD, as Well as to Examine the Effect of Exercise Training on SCs.
COPD (Chronic Obstructive Pulmonary Disease), Sarcopenia in Elderly
Not yet recruitingPhase 2
Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease
Chronic Graft Versus Host Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Fabio Pitta, PhD study chair
Laboratory of Research in Respiratory Physiotherapy, State University of Londrina, Brazil
Karina C. Furlanetto, PT study director
Laboratory of Research in Respiratory Physiotherapy, State University of Londrina, Brazil
Nidia A. Hernandes, PhD principal investigator
Laboratory of Research in Respiratory Physiotherapy, State University of Londrina, Brazil
2 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pulmonary Disease, Chronic Obstructive, run by Universidade Estadual de Londrina at 2 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 11 Jun 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Belgium, Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Fabio Pitta, PhD (+55 43 33712477, fabiopitta@uol.com.br), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Physical activity in daily life (time frame: January 2013 and July 2013. Participants will be followed for the duration of 6 months.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jun 2015.